Literature DB >> 30053078

Editorial: Local Immunotherapy: A Way to Convert Tumors From "Cold" to "Hot".

Marijo Bilusic1, James L Gulley1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 30053078      PMCID： PMC6279267          DOI： 10.1093/jnci/djx132

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  18 in total

Review 1.  The future of immune checkpoint therapy.

Authors:  Padmanee Sharma; James P Allison
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

2.  Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.

Authors:  James L Gulley; Christopher R Heery; Ravi A Madan; Beatriz A Walter; Maria J Merino; William L Dahut; Kwong-Yok Tsang; Jeffrey Schlom; Peter A Pinto
Journal:  Cancer Immunol Immunother       Date:  2013-07-09       Impact factor: 6.968

3.  Tumor targeting in vivo and metabolic fate of 5-[iodine-125]iodo-2'-deoxyuridine following intratumoral injection in patients with colorectal cancer.

Authors:  G Mariani; A Cei; P Collecchi; J Baranowska-Kortylewicz; A D Van den Abbeele; L Di Luca; R Di Stefano; P Viacava; E M Ferdeghini; S Di Sacco
Journal:  J Nucl Med       Date:  1993-07       Impact factor: 10.057

4.  Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.

Authors:  Roger Chou; Shelley Selph; David I Buckley; Rongwei Fu; Jessica C Griffin; Sara Grusing; John L Gore
Journal:  J Urol       Date:  2016-12-24       Impact factor: 7.450

5.  Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

Authors:  Robert H I Andtbacka; Howard L Kaufman; Frances Collichio; Thomas Amatruda; Neil Senzer; Jason Chesney; Keith A Delman; Lynn E Spitler; Igor Puzanov; Sanjiv S Agarwala; Mohammed Milhem; Lee Cranmer; Brendan Curti; Karl Lewis; Merrick Ross; Troy Guthrie; Gerald P Linette; Gregory A Daniels; Kevin Harrington; Mark R Middleton; Wilson H Miller; Jonathan S Zager; Yining Ye; Bin Yao; Ai Li; Susan Doleman; Ari VanderWalde; Jennifer Gansert; Robert S Coffin
Journal:  J Clin Oncol       Date:  2015-05-26       Impact factor: 44.544

6.  Continuous intratumoral infusion of methotrexate for recurrent glioblastoma: a pilot study.

Authors:  D Nierenberg; R Harbaugh; L H Maurer; T Reeder; G Scott; J Fratkin; E Newman
Journal:  Neurosurgery       Date:  1991-05       Impact factor: 4.654

7.  Phase 2 study of intratumoral cisplatin and epinephrine treatment for locally recurrent head and neck tumors.

Authors:  Christian Duvillard; Philippe Romanet; Alain Cosmidis; Nathalie Beaudouin; Bruno Chauffert
Journal:  Ann Otol Rhinol Laryngol       Date:  2004-03       Impact factor: 1.547

8.  Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.

Authors:  Igor Puzanov; Mohammed M Milhem; David Minor; Omid Hamid; Ai Li; Lisa Chen; Michael Chastain; Kevin S Gorski; Abraham Anderson; Jeffrey Chou; Howard L Kaufman; Robert H I Andtbacka
Journal:  J Clin Oncol       Date:  2016-06-13       Impact factor: 44.544

Review 9.  The immunobiology of cancer immunosurveillance and immunoediting.

Authors:  Gavin P Dunn; Lloyd J Old; Robert D Schreiber
Journal:  Immunity       Date:  2004-08       Impact factor: 31.745

10.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.

Authors:  Nicholas McGranahan; Andrew J S Furness; Rachel Rosenthal; Sofie Ramskov; Rikke Lyngaa; Sunil Kumar Saini; Mariam Jamal-Hanjani; Gareth A Wilson; Nicolai J Birkbak; Crispin T Hiley; Thomas B K Watkins; Seema Shafi; Nirupa Murugaesu; Richard Mitter; Ayse U Akarca; Joseph Linares; Teresa Marafioti; Jake Y Henry; Eliezer M Van Allen; Diana Miao; Bastian Schilling; Dirk Schadendorf; Levi A Garraway; Vladimir Makarov; Naiyer A Rizvi; Alexandra Snyder; Matthew D Hellmann; Taha Merghoub; Jedd D Wolchok; Sachet A Shukla; Catherine J Wu; Karl S Peggs; Timothy A Chan; Sine R Hadrup; Sergio A Quezada; Charles Swanton
Journal:  Science       Date:  2016-03-03       Impact factor: 47.728
View more
  5 in total

1.  Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory.

Authors:  Anja C Bloom; Lewis H Bender; Shweta Tiwary; Lise Pasquet; Katharine Clark; Tianbo Jiang; Zheng Xia; Aizea Morales-Kastresana; Jennifer C Jones; Ian Walters; Masaki Terabe; Jay A Berzofsky
Journal:  Oncoimmunology       Date:  2019-07-16       Impact factor: 8.110

2.  GM-CSF elicits antibodies to tumor-associated proteins when used as a prostate cancer vaccine adjuvant.

Authors:  Hemanth K Potluri; Tun L Ng; Michael A Newton; Douglas G McNeel
Journal:  Cancer Immunol Immunother       Date:  2022-02-08       Impact factor: 6.630

Review 3.  Modulation of immune responses using adjuvants to facilitate therapeutic vaccination.

Authors:  Virgil Schijns; Alberto Fernández-Tejada; Žarko Barjaktarović; Ilias Bouzalas; Jens Brimnes; Sergey Chernysh; Sveinbjorn Gizurarson; Ihsan Gursel; Žiga Jakopin; Maria Lawrenz; Cristina Nativi; Stephane Paul; Gabriel Kristian Pedersen; Camillo Rosano; Ane Ruiz-de-Angulo; Bram Slütter; Aneesh Thakur; Dennis Christensen; Ed C Lavelle
Journal:  Immunol Rev       Date:  2020-06-28       Impact factor: 12.988

Review 4.  Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor.

Authors:  Kelly M Hotchkiss; John H Sampson
Journal:  J Neurooncol       Date:  2020-08-19       Impact factor: 4.130

Review 5.  Theoretical premises of a "three in one" therapeutic approach to treat immunogenic and nonimmunogenic cancers: a narrative review.

Authors:  Anastasia S Proskurina; Vera S Ruzanova; Alexandr A Ostanin; Elena R Chernykh; Sergey S Bogachev
Journal:  Transl Cancer Res       Date:  2021-11       Impact factor: 1.241
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.